Cholesterol Guideline Hub
The purpose of the 2018 ACC/AHA Blood Cholesterol guideline is to address the practical management of patients with high blood cholesterol and related disorders. Since the 2013 ACC/AHA cholesterol guideline, newer cholesterol-lowering agents (non-statin drugs) have been introduced and subjected to randomized controlled trials, including ezetimibe and PCSK9 inhibitors. Most patients with Atherosclerotic Cardiovascular Disease are treated with statins alone. This guideline pays consistent attention to a clinician–patient risk discussion for making shared decisions. This clinician–patient risk discussion can include other risk-enhancing factors, and when risk status is uncertain, a coronary artery calcium score is an option to facilitate decision-making in adults ≥40 years of age.
Central Illustration: 2018 ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- Guidelines, Biomarkers, Coronary Artery Calcium Score, Pharmacological, Cardiovascular Disease, Cholesterol, LDL-Cholesterol, Diabetes Mellitus, Drug Therapy
TOOLS & TIPS
The American College of Cardiology (ACC)—along with collaborative societies—create Clinical Practice Guidelines, which become ACC policy at the time of publication. All Clinical Practice Guidelines undergo rigorous peer review that is independent of the Editors/editorial processes of the Journal of the American College of Cardiology (JACC). JACC Editors receive no compensation from the publication of the guidelines nor other ACC clinical/policy documents. For more information on guideline processes, click here: About Guidelines and Clinical Documents